Login / Signup

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.

Mark R MiddletonEmma DeanThomas R J EvansGeoffrey I ShapiroJohn PollardBart S HendriksMartin FalkIvan Diaz-PadillaRuth Plummer
Published in: British journal of cancer (2021)
NCT02157792.
Keyphrases
  • open label
  • dna damage response
  • locally advanced
  • placebo controlled
  • squamous cell carcinoma
  • dna damage
  • oxidative stress
  • study protocol